PDCD1 and cancer: The PD-1/programmed death-ligand 1 (PD-L1) inhibitory axis has been one of the well-studied inhibitory immune checkpoint axes in cancers; thus, targeting this axis via monoclonal antibodies was among the attempts to stimulate anti-tumoral immune responses [7].